ABBV Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 май 2024 @ 23:00):

Stats
Объем за сегодня	4.61M
Средний объем	5.73M
Рыночная капитализация	284.74B
EPS	$2.79 ( 2024-04-26 )
Дата следующего отчета о доходах	( $3.03 ) 2024-07-25
Last Dividend	$1.550 ( 2024-04-12 )
Next Dividend	$0 ( N/A )
P/E	47.86
ATR14	$0.118 (0.07%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Quaggin Susan E	Buy	82	Stock Equivalent Units
2024-03-31	Alpern Robert J	Buy	41	Stock Equivalent Units
2024-03-31	Rapp Edward J	Buy	212	Stock Equivalent Units
2024-03-20	Donoghoe Nicholas	Sell	21 082	Common Stock, $0.01 par value
2024-03-18	Stewart Jeffrey Ryan	Buy	26 110	Common Stock, $0.01 par value

INSIDER POWER
2.46
Last 100 transactions
Buy: 975 676 \| Sell: 912 577

Объем Корреляция

Длинно: 0.37 (neutral)

Кратко: 0.83 (strong)

Signal:(65.896) Same movement expected

Abbvie Inc Корреляция

10 Самые положительные корреляции
YSAC	0.891
MOS	0.887
TDI	0.882
NANR	0.865
BML-PJ	0.864
CHH	0.864
VAL	0.86
TMO	0.858
VLTA	0.853
PACK	0.847

10 Самые отрицательные корреляции
TGH	-0.863
KURE	-0.861
PBC	-0.86
FRGE	-0.859
ALCC	-0.856
SID	-0.854
CE	-0.847
MX	-0.847
FDD	-0.844
WFC-PD	-0.839

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Abbvie Inc Корреляция - Валюта/Сырье

-0.52
( weak negative )

-0.63
( weak negative )

0.00
( neutral )

-0.15
( neutral )

0.71
( moderate )

0.16
( neutral )

Abbvie Inc Финансовые показатели

Annual	2023
Выручка:	$54.32B
Валовая прибыль:	$45.54B (83.84 %)
EPS:	$2.73

FY	2023
Выручка:	$54.32B
Валовая прибыль:	$45.54B (83.84 %)
EPS:	$2.73

FY	2022
Выручка:	$58.05B
Валовая прибыль:	$40.64B (70.00 %)
EPS:	$6.65

FY	2021
Выручка:	$56.20B
Валовая прибыль:	$38.75B (68.96 %)
EPS:	$6.53

Financial Reports:

No articles found.

Abbvie Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.410 (N/A)	$1.410 (N/A)	$1.480 (N/A)	$1.480 (N/A)	$2.96 (N/A)	$1.480 (N/A)	$1.550 (N/A)	$1.550 (N/A)	$0 (N/A)	$0 (N/A)

Abbvie Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 4.65 - low (54.43%) | Divividend Growth Potential Score: 4.92 - Stable (1.56%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.400	2013-01-11
Last Dividend	$1.550	2024-04-12
Next Dividend	$0	N/A
Payout Date	2024-05-15
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	$44.05	--
Avg. Dividend % Per Year	3.70%	--
Score	4.89	--
Div. Sustainability Score	4.65
Div.Growth Potential Score	4.92
Div. Directional Score	4.79	--

Next Divdend (Est)
(2024-07-01)

$1.580 Estimate 75.00 %

Dividend Stability

1.00 Excellent

Dividend Score

4.89

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2013	$1.600	4.56%
2014	$1.660	3.19%
2015	$2.02	3.07%
2016	$2.28	3.96%
2017	$2.56	4.10%
2018	$3.59	3.65%
2019	$4.28	4.80%
2020	$4.72	5.27%
2021	$5.20	4.93%
2022	$5.64	4.16%
2023	$7.40	4.56%
2024	$3.10	1.94%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.110	1.500	7.79	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.525	1.500	5.28	7.92	[0.1 - 1]
payoutRatioTTM	1.313	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	8.35	1.000	8.02	8.02	[3 - 30]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.15	2.00	4.93	9.85	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.334	1.334	[0.2 - 0.8]
operatingProfitMarginTTM	0.271	1.000	6.58	6.58	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.66	1.000	5.29	0	[1 - 100]
returnOnEquityTTM	0.525	2.50	6.97	7.92	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.15	2.00	6.62	9.85	[0 - 30]
dividendYielPercentageTTM	3.77	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.49	2.00	6.50	10.00	[0 - 30]
payoutRatioTTM	1.313	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-0.836	1.500	-8.91	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.343	1.000	3.93	0	[0.1 - 0.5]
Total Score				4.92

Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.